Extensive data are rapidly accumulating that several sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor (GLP-1) agonists reduce ASCVD events in patients with diabetes [40, 45]. This evidence concerns the gene SLC5A2 and diabetes mellitus.